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53-induced nuclear protein 1 in patients 
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Abstract 
Background: Lung cancer, predominantly non-small-cell lung cancer (NSCLC), is the leading cause of cancer deaths 
worldwide. There is a great need to identify critical effectors involved in metastasis of NSCLC that will facilitate the 
development of new therapeutic strategies. Here we evaluated the potential role of miR-125b in the metastasis of 
NSCLC cells.
Methods: Human NSCLC cells were isolated from surgical tissues with Cancer Cell Isolation Kit. Expressions of miR-
125b and TP53INP1 were detected with real-time PCR and western blot. Human miR-125b mimics, miR-125b inhibitor, 
TP53INP1 expression plasmid and TP53INP1 siRNA were transfected into NSCLC cells with nucleofector transfection 
kit. NSCLC metastasis was determined with adhesion assay, invasive assay and lung tumor metastasis model.
Results: The expression of miR-125b was significantly higher in poorly differentiated NSCLC cells that are endowed 
with high metastatic potentials. Up-regulation of miR-125b could enhance the metastatic potential of NSCLC cells 
in vitro and in vivo, while down-regulation of miR-125b resulted in decreased metastatic potentials in vitro and in vivo. 
Further, tumor protein 53-induced nuclear protein 1 (TP53INP1) was an important target of miR-125b involved in 
metastasis of NSCLC cells. TP53INP1 served as a negative regulator of NSCLC metastasis. Decreased expression of 
TP53INP1 in tumor tissues was inversely associated with their expression of miR-125b, significantly lower in poorly dif-
ferentiated tumors and inversely correlated with the clinical stages in patients with NSCLC.
Conclusions: These findings demonstrated that miR-125b promoted tumor metastasis via targeting TP53INP1 in 
human NSCLC cells, which uncovered a real clinical relevance of microRNAs in tumor biology, and provided novel 
potential candidates for NSCLC clinical practice.
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Background
Lung cancer, especially non-small-cell lung cancer 
(NSCLC), is the most common cause of human cancer 
related mortality [1–4]. Although combined treatments 
including surgery, chemotherapy, radiotherapy and tar-
geted therapy were applied in clinical management, the 
current outcome of NSCLC patients is still far from satis-
fied, which is mostly because of NSCLC metastasis [4–7]. 
Therefore, exploration of critical effectors involved in 
NSCLC metastasis is urgently needed.
MicroRNAs (miRNAs) are non-coding RNAs and 
regulate target genes at post-transcriptional level [8, 9]. 
It is well acknowledged that deregulation of miRNAs 
was involved in tumor initiation and progression [10]. 
MiR-125b, a human homologue of lin-4, was reported 
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to be involved in tumor progression [11–15]. MiR-125b 
could regulate tumor cellular apoptosis and proliferation 
[16–21]. In NSCLC, serum miR-125b was significantly 
increased and was positively associated with NSCLC 
stages and poor patient survival [9, 10]. Of note, miR-
125b expression in poorly differentiated NSCLC was 
significantly higher than those in well and moderately 
differentiated NSCLC [9, 10]. These findings indicated an 
involvement of miR-125b in NSCLC metastasis, which is 
largely undefined.
In this study, we evaluated the effect of miR-125b on 
metastasis of lung cancer cells from NSCLC patients. 
We observed a significant higher expression level of miR-
125b in poorly differentiated NSCLC cells. Of important, 
management of miR-125b expression could modulate the 
NSCLC metastasis in  vitro and in  vivo. Further, tumor 
protein 53-induced nuclear protein 1 (TP53INP1) was 
identified as a critical target of miR-125b involved in 
NSCLC metastasis. Our findings provided new insights 
into the function of miR-125b during the metastasis of 
human NSCLC and were helpful for developing novel 
strategy in treatment of NSCLC patients.
Results
High expression of miR‑125b in poorly differentiated 
human NSCLC
Detection of miR-125b expression in clinical NSCLC 
patients showed that the expression level of miR-125b was 
higher in lung cancer tissue compared with adjacent tissue 
(Fig.  1a). We further showed that the level of miR-125b 
was significantly higher in poorly differentiated NSCLC 
than those in well and moderately differentiated cancers 
(Fig.  1b). Besides, miR-125b expression was positively 
correlated with the clinical stages of patients with NSCLC 
(Fig.  1c). These findings suggested that miR-125b might 
be involved in NSCLC metastasis of clinical patients.
Up‑regulation of miR‑125b promoted human NSCLC 
metastasis
To determine the effect of miR-125b on metastatic poten-
tial of human NSCLC, NSCLC cells were transfected with 
miR-125b mimics and then analyzed for their metastatic 
potential. As shown in Fig.  2a, transfection with miR-
125b mimics effectively enhanced its expression level 
in NSCLC cells (p < 0.05). Given that adhesion of tumor 
cells to extra-cellular matrix and basement membranes 
are considered to be the initial step in the invasive process 
for metastatic tumor cells, NSCLC cells transfected with 
miR-125b mimics were examined for their adhesion activi-
ties to the substrates precoated with fibronectin, which 
is a basement member component. We found that trans-








































































Fig. 1 Expression of miR-125b in human NSCLC cells. a Relative 
expression of miR-125b was determined by real time PCR in 20 NSCLC 
lung cancer samples. b The relative expression of miR-125b in the 
well, moderately and poorly differentiated tumor tissues were shown. 
c The correlation between the relative miR-125b expression and the 
TNM stage of NSCLC patients was analyzed. Each dot represented the 
results from one patient
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adhesion activities of NSCLC cells (Fig. 2b). Then, we ana-
lyzed the invasive potential of NSCLC cells after transfec-
tion with miR-125b mimics, and revealed that transfection 
with miR-125b mimics effectively enhanced the invasion 
of NSCLC cells (Fig. 2c). To confirm these results in vivo, 
nude mice were challenged with NSCLC cells that were 
transfected with miR-125b mimics or control, respectively. 
Over-expression of miR-125b significantly enhanced the 
lung tumor burdens of NSCLC cells (Fig. 2d). These results 
demonstrated that up-regulation of miR-125b could pro-
mote the metastatic potential of human NSCLC.
Down‑regulation of miR‑125b reduced human NSCLC 
metastasis
To further elucidate the effect of miR-125b on the meta-
static potential of human NSCLC, NSCLC cells were trans-
fected with miR-125b inhibitors and then analyzed for their 
metastatic potential. As shown in Fig. 3a, transfection with 
miR-125b inhibitors effectively decreased its expression 
level in NSCLC cells. Further, transfection with miR-125b 
inhibitors significantly inhibited the adhesion activities of 
NSCLC cells (Fig.  3b). Expectedly, transfection with miR-
125b inhibitors also effectively abrogated the invasion of 
NSCLC cells (Fig.  3c). To further confirm this phenom-
enon in vivo, nude mice were challenged with NSCLC cells 
that were transfected with miR-125b inhibitors or control, 
respectively. Decreased expression of miR-125b consid-
erably reduced the lung tumor burdens of NSCLC cells 
(Fig. 3d). These results demonstrated that down-regulation 
of miR-125b could inhibit the metastatic potential of human 
NSCLC.
TP53INP1 was the dominant target of miR‑125b 
in regulating NSCLC metastasis
To further understand the effect of miR-125b on the 
metastasis of human NSCLC, we predicted the targets 
of miR-125b by prediction programs including Tar-
getScan and PicTar, and selected eight possible target 



































































Fig. 2 Up-regulation of miR-125b enhanced NSCLC metastasis. a NSCLC cells from different patients were transfected with miR-125b mimics for 
12 h and then assayed for their expressions of miR-125b. Each dot represented the results from one patient. b, c NSCLC cells from different patients 
were transfected with miR-125b mimics or the control, respectively, and then assayed for their adhesion activity (n = 4) and invasion (n = 5). d 
Nude mice were challenged LPS and NSCLC cells that were transfected with miR-125b mimics or the control. Lung tumor burden was detected by 
analyzing lung weight. Data were presented as means (±SD) from five nude mice in each group
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including STARD13, ZNF792, SH3TC2, IRF4, FUT4, 
BAK1, ARID3B, and TP53INP1 for real time PCR anal-
ysis. We found that the expression of TP53INP1 exhib-
ited a dramatically elevation in NSCLC cells transfected 
with miR-125b inhibitors (Fig.  4a). To confirm this 
result, we performed western blot to detect the expres-
sion of TP53INP1 in NSCLC cells transfected with 
miR-125b inhibitors. We found that the protein level of 
TP53INP1 was significantly increased by transfection 
with miR-125b inhibitors in NSCLC cells (Fig. 4b). Given 
that TP53INP1 has been proved to be a direct target of 
miR-125b [27], we further evaluated the possible role 
of TP53INP1 in tumor promoting activity of miR-125b. 
We found that transfection of miR-125b mimics failed 
to enhance the adhesion activity and invasion of NSCLC 
cells that were co-transfected with TP53INP1 expres-
sion vector (Fig.  4c–e). To confirm this phenomenon, 
NSCLC cells were co-transfected with TP53INP1 siRNA 
and miR-125b inhibitors, and then analyzed for their 
metastatic potential. As shown in Fig. 4f–h, transfection 
with TP53INP1 siRNA effectively decreased TP53INP1 
expression in NSCLC cells and abrogated the effect of 
miR-125b inhibitors on adhesion activity and invasion of 
NSCLC cells. These results suggested that TP53INP1 was 
a bona fide target of miR-125 in regulating the metastasis 
of human NSCLC.
TP53INP1 negatively regulated the metastasis of human 
NSCLC
We detected the direct effect of TP53INP1 on the 
metastasis of NSCLC cells. NSCLC cells were trans-
fected with TP53INP1 expression vector and then 
analyzed for their adhesion activity and invasion. We 
found that transfection with TP53INP1 expression 
vector effectively inhibited the adhesion activity and 
invasion of NSCLC cells (Fig. 5a, b). Transfection with 
TP53INP1 siRNA significantly increased the adhesion 
activity and invasive potential of NSCLC cells (Fig.  5c, 
b



































































Fig. 3 Down-regulation of miR-125b reduced NSCLC metastasis. a NSCLC cells from different patients were transfected with miR-125b inhibitors for 
12 h and then assayed for their expression of miR-125b. Each dot represented the results from one patient. b, c NSCLC cells from different patients 
were transfected with miR-125b inhibitors or the control, respectively, and then assayed for their adhesion activity (n = 4) and invasion (n = 5). d 
Nude mice were challenged LPS and NSCLC cells that were transfected with miR-125b inhibitors or the control. Lung tumor burden was detected 
by analyzing lung weight. Data were presented as means (±SD) from five nude mice in each group










































































































































































































































































































Fig. 4 TP53INP1 was a functional target of miR-125b. a NSCLC cells from different patients (n = 3) were transfected with miR-125b inhibitors for 
12 h and then assayed for their expression of the indicated genes using real time PCR. b NSCLC cells from one patient were transfected with miR-
125b inhibitors for 48 h and then assayed for their expression of TP53INP1 using western blot. c NSCLC cells from different patients were transfected 
with TP53INP1 expression vector for 12 h and then assayed for their expression of TP53INP1 mRNA level. d, e NSCLC cells from different patients 
were co-transfected with miR-125 mimics and TP53INP1 expression vector, and then assayed for their adhesion activity (n = 4) and invasion (n = 5). 
f NSCLC cells from different patients were transfected with TP53INP1 siRNA or the control for 12 h and then assayed for their expression of TP53INP1. 
g, h NSCLC cells from different patients were co-transfected with miR-125 inhibitors and TP53INP1 siRNA, and then assayed for their adhesion activ-
ity (n = 4) and invasion (n = 5). Each dot represented the results from one patient
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d). In consistent, enforced TP53INP1 alleviated the 
lung tumor burden of NSCLC cells, while decreased 
TP53INP1 enhanced the lung tumor burden of NSCLC 
cells (Fig.  5e, f ). These data suggested that TP53INP1 
was a negative regulator of human NSCLC metastasis.
TP53INP1 expression in tumor tissues was correlated 
with miR‑125b expression and clinical parameters 
in patients with NSCLC
To further investigate the clinical relevance of our above 
findings, we detected the relationship between the 
a





























































































Fig. 5 TP53INP1 suppressed NSCLC metastasis. a, b NSCLC cells from different patients were transfected with TP53INP1 expression vector and then 
assayed for their adhesion activity (n = 4) and invasion (n = 5). c, d NSCLC cells from different patients were transfected with TP53INP1 siRNA and 
then assayed for their adhesion activity (n = 4) and invasion (n = 4). e, f Nude mice were challenged LPS and NSCLC cells that were transfected 
with TP53INP1 expression vector, TP53INP1 siRNA or the controls. Lung tumor burden was detected by analyzing lung weight. Data were presented 
as means (±SD) from five nude mice in each group
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expression of miR-125b and TP53INP1 in clinical NSCLC 
patients. As shown in Fig. 6a, the expression of TP53INP1 
was significantly lower in tumor tissues compared with 
adjacent tissues. We further revealed that the expression 
of miR-125b was inversely correlated with the expression 
level of TP53INP1 in tumor tissues (Fig. 6b). The expres-
sion of TP53INP1 was significantly decreased in poorly 
differentiated NSCLC than those in well and moderately 
differentiated cancers, and was inversely associated with 
the clinical stages of NSCLC patients (Fig.  6c, d). These 
findings assigned TP53INP1 as an important target for 
miR-125b in promoting the metastasis of human NSCLC.
Discussion
Tumor metastasis is the most prominent problem in 
clinical treatment of cancer, as most cancer mortality 
is associated with disseminated disease rather than the 
primary tumor [22]. However, the underlying mecha-
nisms involved in the metastasis of tumor still remain 
unclear. MiRNAs are known to regulate the expres-
sion of genes involved in tumor initiation, prolifera-
tion, apoptosis and metastasis [22, 23]. In present study, 
we reported the critical role of miR-125b in regulat-
ing the metastasis of NSCLC. We observed a higher 
expression level of miR-125b in poorly differentiated 
NSCLC cells. We validated the elevated expression of 
miR-125b in tumor tissues and its positive association 
with the clinical stages. Of important, up-regulation 
of miR-125b expression enhanced NSCLC metastatic 
potential in vitro and in vivo, while down-regulation of 
miR-125b expression decreased their metastatic poten-
tials. Our findings were consistent with recent study 
which showed that serum miR-125b was significantly 
increased in NSCLC patients, was positively associated 
with NSCLC stages and poor patient survival, and was 
significantly higher in poorly differentiated NSCLC [9, 
10]. Our findings could enlarge our understanding of 





































































































Fig. 6 Expression of TP53INP1 in tumor tissues of NSCLC patients. a Relative expression of TP53INP1 was determined by real time PCR in 20 NSCLC 
lung cancer samples. b The correlation between the relative miR-125b expression and the relative TP53INP1 expression in NSCLC patients was ana-
lyzed. c The relative expression of TP53INP1 in the well, moderately and poorly differentiated tumor tissues were shown. d The correlation between 
the relative TP53INP1 expression and the TNM stage of NSCLC patients was analyzed. Each dot represented the results from one patient
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that miR-125b was a promising target for treatment of 
NSCLC.
TP53INP1 is widely recognized as a tumor suppres-
sor gene with anti-proliferative and pro-apoptotic func-
tions [24, 25]. The expression of TP53INP1 was reduced 
in various human cancers, e.g., breast, pancreas and gas-
tric cancers [26–28]. Of interest, reduction of TP53INP1 
expression in gastric cancer was closely correlated with 
their aggressive phenotypes [28]. These findings sug-
gested TP53INP1 as an important effector in tumor sup-
pression. In this study, we found that TP53INP1 was an 
important target of miR-125b in regulating the metastasis 
of NSCLC. We found that over-expression of TP53INP1 
could significantly abrogate the tumor promoting effect 
of miR-125b. Further, up-regulation of TP53INP1 could 
significantly inhibit the metastasis of NSCLC cells. 
Decreased expression of TP53INP1 effectively promoted 
NSCLC metastasis. Finally, we found that the decreased 
expression of TP53INP1 was inversely correlated with 
the expression of miR-125b and the clinical stages, and 
was decreased further in poorly differentiated tumors 
in patients with NSCLC. In NSCLC cells without treat-
ment, expression of miR-125b was also negatively associ-
ated with TP53INP1 expression (Additional file 1: Figure 
S1). Our findings were, to some extent, in line with recent 
study which showed that miR-125b could promote prolif-
eration and migration of type II endometrial carcinoma 
cells through targeting TP53INP1 [29]. However, the pre-
cise mechanisms for how TP53INP1 functioned in metas-
tasis of NSCLC undoubtedly deserved successive studies. 
Besides, the number of patients enrolled in this study was 
relatively limited and additional study on a large size of 
clinical samples might substantiate our findings.
Conclusions
Herein, we reported a critical role of miR-125b in 
NSCLC metastasis via targeting TP53INP1 in clinical 
patients. These findings were derived from clinical sam-
ples and thus closely reflected the real clinical relevance. 
MiR-125b and TP53INP1 might be promising targets 




The human study was approved by the Ethics Commit-
tee of Tongji University. Totally 37 NSCLC patients were 
enrolled in this study and given written informed consent 
before collecting surgical tissues and clinical parameters. 
Review of pathology reports confirmed the diagnosis. 
Subjects with autoimmune diseases or infections were 
excluded. Information regarding clinical pathological 
characteristics of patients was summarized in Table 1.
Reagents and cell culture
NSCLC cells were isolated from surgical tumor tissues 
using Cancer Cell Isolation Kit (Panomics). According 
to the manufacture’s instructions, cells were cultured for 
4 days at 37  °C under 5 % CO2 in complete RPMI 1640 
medium (GIBCO, containing 10 % heat-inactivated fetal 
bovine serum supplemented with 2  mM glutamine, 
100  IU/ml penicillin and 100  mg/ml streptomycin sul-
fate), and used for experimental research. MiR-125b 
mimics and miR-125b inhibitor were from Ribobio 
(Guangzhou, China). Human TP53INP1 expression 
plasmid was purchased from Origen. Human TP53INP1 
siRNA was from Santa Cruz. The nucleofector transfec-
tion kit was purchased from Amaxa.
Adhesion assay
Cell adhesion assay was assayed as described previ-
ously [22, 30]. In brief, microtiter wells were coated with 
fibronectin (Sigma, St. Louis, MO, USA) overnight and 
were blocked for 30 min with 0.5 % BSA in PBS. NSCLC 
cells were suspended at a final concentration of 5 × 105 
cells/ml in serum-free medium for seeding. The MTT-
assay (Cayman) was used to determine the number of 
remaining cells (adherent cells).
Invasive assay
The BD Biocoat Matrigel Invasion Chamber assay was 
performed as described by the manufacturers (8  μm, 
BD Bioscience). Briefly, the Matrigel inserts were rehy-
drated and 5  ×  104 NSCLC cells were resuspended in 
0.5  mL of serum-free media and then seeded onto the 
upper chamber of Matrigel-coated filters. In the lower 
Table 1 The clinical pathological characters of  the NSCLC 
patients
Lymph nodal metastasis is according to pathological diagnosis and clinical 
palpation. Clinical stage is according to TNM stage
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chambers, 0.75 mL of complete medium was added as a 
chemoattractant. The whole chamber was placed in one 
well of a 24-well plate, and cells were cultured in routine 
conditions. After 24 h, the cells on the upper side of the 
chamber were scraped, and the ones on the lower side of 
the chamber were fixed by methanol, stained with hema-
toxylin, and invaded cells were counted under the micro-
scope. Five predetermined fields were counted for each 
membrane, and the mean values from three independent 
experiments in triplicates were used. Data are expressed 
as the percentage of invasion through the Matrigel 
Matrix and membrane relative to the migration through 
the control membrane according to the manufacturer’s 
manual.
Real‑time PCR
Quantitative Real-time RT-PCR was performed as pre-
viously described [31, 32]. All the primers and probes 
were obtained from Applied Biosystems. Total RNA was 
extracted using TRIzol reagent. cDNA was synthesized 
with the PrimeScript RT reagent Kit (TaKaRa). Quan-
titative RT-PCR (qRT-PCR) analyses were carried out 
to detect mRNA expression using SYBR Premix Ex Taq 
(TaKaRa), and β-actin was used as an internal control. 
TaqMan micro-RNA assays (Applied Biosystems) were 
used to quantitative the expression levels of mature miR-
125b, and U6 small nuclear RNA was used as an internal 
control.
Western blotting
Cells were lysed with M-PER protein extraction reagent 
(Pierce) supplemented with a protease inhibitor cocktail. 
Cytoplasmic and nuclear extracts were prepared using 
NE-PER nuclear and cytoplasmic extraction reagents 
(Pierce). After centrifugation at 13,000g under 4  °C for 
15 min, the supernatants were collected, and the protein 
concentration of the extracts was measured by BCA Pro-
tein Assay (Pierce) according to manufacturer’s instruc-
tions. Twenty micrograms of the protein were loaded 
onto 10 % SDS–polyacrylamide gels and transferred for 
90 min at 100 V onto polyvinylidene fluoride membranes 
using a wet transfer system. The membranes were washed 
in 5 % skim milk in phosphate buffered saline plus 0.05 % 
Tween 20 (PBST) for 2  h in order to block nonspecific 
protein binding sites on the membrane. Immunoblot-
ting was performed using monoclonal antibodies to 
TP53INP1 and GAPDH (Sigma) at a dilution of 1:1000 in 
nonfat milk Tris buffer. The membrane was then washed 
in PBST, probed with a secondary anti-rabbit antibody 
conjugated to horseradish peroxidase (Amersham Life 
Sciences) at a dilution of 1:5000, developed using an ECL 
Western Blotting KIT (Pierce), and exposed to X-ray film 
(Kodak).
Lung tumor metastasis model
BALB/c nude mice were purchased from animal center 
of Tongji University and housed under specific patho-
gen-free conditions. Lung tumor metastasis model were 
performed as previously described [33, 34]. Briefly, nude 
mice (n =  5 per group) were intratracheally challenged 
with LPS (10  μg/mouse), and injected with 4  ×  105 
NSCLC cells via tail vein 6 h later. Two weeks later, nude 
mice were detected for their lung tumor metastases/bur-
dens that were reflected by total lung weights. The mice 
experiments were approved by Ethics Committee of 
Tongji University.
Statistical analyses
T tests and Pearson correlation were used for statistical 
analyses using the program PRISM 6.0 (GraphPad Soft-
ware Inc., San Diego, CA, USA). A value of P < 0.05 was 
considered statistically significant.
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